Healius's Pathology Profitability Remains Challenged -- Market Talk

Dow Jones

2024/11/18

2227 GMT - Healius's recent performance by its pathology business underwhelms Citi. Healius indicates profitability of Pathology division in 1H would be broadly in line with the same period a year earlier. That implies some A$4 million Ebit, well below Citi's A$14 million forecast and an even bigger miss to consensus hopes. It also comes despite a 5.9% improvement in revenue in FY 2025 so far. Healius says it has faced labor cost rises and is investing to keep its revenue growing. "Healius believes its share has stabilized in the last six months, albeit it seems to have come at a cost to profitability," says analyst Mathieu Chevrier. Citi retains a sell call on Healius's stock. (david.winning@wsj.com; @dwinningWSJ)

(END) Dow Jones Newswires

November 17, 2024 17:27 ET (22:27 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2484652594"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484652594\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2484652594?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 06:27","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484652594","market":"sg","top_or_hot":-1,"title":"Healius's Pathology Profitability Remains Challenged -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2227 GMT - Healius's recent performance by its pathology business underwhelms Citi. Healius indicates profitability of Pathology division in 1H would be broadly in line with the same period a year earlier. That implies some A$4 million Ebit, well below Citi's A$14 million forecast and an even bigger miss to consensus hopes. It also comes despite a 5.9% improvement in revenue in FY 2025 so far. Healius says it has faced labor cost rises and is investing to keep its revenue growing. \"Healius believes its share has stabilized in the last six months, albeit it seems to have come at a cost to profitability,\" says analyst Mathieu Chevrier. Citi retains a sell call on Healius's stock. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 17, 2024 17:27 ET (22:27 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Healius's Pathology Profitability Remains Challenged -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHealius's Pathology Profitability Remains Challenged -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2024-11-18 06:27</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     2227 GMT - Healius's recent performance by its pathology business underwhelms Citi. Healius indicates profitability of Pathology division in 1H would be broadly in line with the same period a year earlier. That implies some A$4 million Ebit, well below Citi's A$14 million forecast and an even bigger miss to consensus hopes. It also comes despite a 5.9% improvement in revenue in FY 2025 so far. Healius says it has faced labor cost rises and is investing to keep its revenue growing. \"Healius believes its share has stabilized in the last six months, albeit it seems to have come at a cost to profitability,\" says analyst Mathieu Chevrier. Citi retains a sell call on Healius's stock. (david.winning@wsj.com; @dwinningWSJ) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 17, 2024 17:27 ET (22:27 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7501","symbol_name":"新冠治疗股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2484652594","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484652594","pubTimestamp":1731882420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"2227 GMT - Healius's recent performance by its pathology business underwhelms Citi. Healius indicates profitability of Pathology division in 1H would be broadly in line with the same period a year earlier. That implies some A$4 million Ebit, well below Citi's A$14 million forecast and an even bigger miss to consensus hopes. It also comes despite a 5.9% improvement in revenue in FY 2025 so far. Healius says it has faced labor cost rises and is investing to keep its revenue growing. \"Healius believes its share has stabilized in the last six months, albeit it seems to have come at a cost to profitability,\" says analyst Mathieu Chevrier. Citi retains a sell call on Healius's stock. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7501":"新冠治疗股","BK7124":"保健护理服务","BK7509":"中概股","HLS.AU":"HEALIUS LTD"},"translate_title":"Healius的病理学盈利能力仍面临挑战——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HLS.AU":0.9},"content_text":"2227 GMT - Healius's recent performance by its pathology business underwhelms Citi. Healius indicates profitability of Pathology division in 1H would be broadly in line with the same period a year earlier. That implies some A$4 million Ebit, well below Citi's A$14 million forecast and an even bigger miss to consensus hopes. It also comes despite a 5.9% improvement in revenue in FY 2025 so far. Healius says it has faced labor cost rises and is investing to keep its revenue growing. \"Healius believes its share has stabilized in the last six months, albeit it seems to have come at a cost to profitability,\" says analyst Mathieu Chevrier. Citi retains a sell call on Healius's stock. (david.winning@wsj.com; @dwinningWSJ) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2024 17:27 ET (22:27 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}